Ranbaxy speeds development of cancer biosimilars; Ascletis inks Alnylam pact; Arena files for Belviq OK;

 @FierceBiotech: Duke and Scripps grab $31M for HIV /AIDS vaccine research, $186M to be awarded over six years. Story | Follow @FierceBiotech

 @JohnCFierce: Ascletis gets China development rights to Alnylam liver cancer drug--no terms announced. More | Follow @JohnCFierce

 @RyanMFierce: Here's Pfizer's 2011 ASCO poster on the FAK inhibitor. Item | Follow @RyanMFierce

> India's Ranbaxy Laboratories says it expects to release three cancer biosimilars by 2015. The first is due to arrive next year. Story

> Shares of Hemispherx Biopharma rose yesterday after the company reported that it met with FDA reps. The biotech says the FDA agreed to accept for review new analyses of data from its AMP-516 Phase III study in support of its NDA for Ampligen. Release

> Ascletis--a U.S./China joint venture--has inked its first deal. The biotech says it has licensed the rights to develop Alnylam's ($ALNY) RNAi treatment for liver cancers for the Chinese market. Release

> Arena Pharmaceuticals ($ARNA) has filed its weight drug Belviq for approval in Switzerland. Story

> Cubist Pharmaceuticals launched pivotal Phase III studies of CB-315 in patients with Clostridium difficile-associated diarrhea, enrolling the first patient in the first of two planned identical global trials. Release

Pharma News

 @FiercePharma: Failing with Forest CEO, Icahn is now pressing non-exec board members to settle proxy contest--Reuters More | Follow @FiercePharma

> Foreign demand saves Ipsen's primary-care plant. Story

> Emerging markets to dominate as drug sales hit $1.2T. More

> J&J to tighten up on oversight in wake of recalls, lawsuits. News

> Sanofi Pasteur plant idles for fixes after vax recall. Article

Medical Device News

@FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

@MarkHFierce: Hologic's acquisition of Gen-Probe closes at the end of the month. More | Follow @MarkHFierce

@DamianFierce: Becton Dickinson has bought Safety Syringes to boost its injectables business. Item | Follow @DamianFierce

> Facing long odds, House again votes to repeal healthcare reform. Story

> Hologic's $3.7B buyout of diagnostics outfit Gen-Probe to close Aug. 1. News

> J&J confronts lawsuits over another all-metal hip implant. More

> FDA slaps Class I tag on GE's ventilator recall. Article

CRO News

 @NesaNFierce: ERT is striking the ePRO iron while it's hot, purchasing Invivodata. How many CROs take advantage of electronic data? Story | Follow @NesaNFierce

> Study shows no difference in data quality from CROs in developing countries. News

> Pharma cuts mean more expertise for CROs. Article

> Toshiba's latest TV ad doesn't leave ACRO laughing. Story

> EU preps simplified clinical trial rules for drug developers. News

> Polish market for clinical trials grows. Item

Pharma Manufacturing News

 @EricPFierce:  Flooding leads to mold, leads to recall, leads to cancer drug shortage for Sanofi. More | Follow @EricPFierce

> Bristol-Myers expanding again in Puerto Rico. Story

> Kaluga Russia sets itself up as drugmaking epicenter. News

> Hospira shortage can't be blamed for woman's blindness. Article

Vaccines News

> Norway's Bionor snags $1.7 million for HIV vaccine research. Article

> Australia backs plan to give HPV vax Gardasil to boys. More

> Duke and Scripps grab $31M for HIV/AIDS vax research. News

And Finally… In the wake of Big Pharma layoffs, CROs are snatching up experienced clinical trials experts. Story

 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.